Literature DB >> 33552388

Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer.

C B Mainor1, C Isaacs2.   

Abstract

PURPOSE OF REVIEW: We review the management for unaffected BRCA1/2 mutation carriers and the local management of early stage breast cancer. RECENT
FINDINGS: For unaffected BRCA1/2 mutation carriers, surveillance includes annual magnetic resonance imaging (MRI) and mammogram (MG). Novel imaging modalities, including abbreviated protocol MRI, ultrafast/accelerated MRI, and contrast-enhanced digital mammography are being investigated. Risk reducing mastectomy (RRM) should be considered, and nipple-areolar sparing mastectomy (NSM) is now an option. Additionally, risk reducing salpingo-oophorectomy (RRSO) is strongly recommended as it reduces mortality.In BRCA1/2 mutation carriers with breast cancer, BCT is an appropriate treatment option but to reduce risk of second primary, mastectomy and contralateral risk-reducing mastectomy should be considered.

Entities:  

Keywords:  BRCA1; BRCA2; Breast Cancer; Breast conserving therapy

Year:  2020        PMID: 33552388      PMCID: PMC7863621          DOI: 10.1007/s12609-019-00350-2

Source DB:  PubMed          Journal:  Curr Breast Cancer Rep        ISSN: 1943-4588


  54 in total

1.  Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; William D Foulkes; Nadine Tung; Charmaine Kim-Sing; Olufunmilayo I Olopade; Andrea Eisen; Barry Rosen; Carrie Snyder; Shelley Gershman; Ping Sun; Steven A Narod
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

2.  Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.

Authors:  Wendie A Berg; Zheng Zhang; Daniel Lehrer; Roberta A Jong; Etta D Pisano; Richard G Barr; Marcela Böhm-Vélez; Mary C Mahoney; W Phil Evans; Linda H Larsen; Marilyn J Morton; Ellen B Mendelson; Dione M Farria; Jean B Cormack; Helga S Marques; Amanda Adams; Nolin M Yeh; Glenna Gabrielli
Journal:  JAMA       Date:  2012-04-04       Impact factor: 56.272

3.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Authors:  Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

4.  Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.

Authors:  Alexandra J van den Broek; Marjanka K Schmidt; Laura J van 't Veer; Hester S A Oldenburg; Emiel J Rutgers; Nicola S Russell; Vincent T H B M Smit; Adri C Voogd; Linetta B Koppert; Sabine Siesling; Jan J Jobsen; Pieter J Westenend; Flora E van Leeuwen; Rob A E M Tollenaar
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969

5.  Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?

Authors:  Carlos A Garcia-Etienne; Monica Barile; Oreste D Gentilini; Edoardo Botteri; Nicole Rotmensz; Andrea Sagona; Gabriel Farante; Viviana Galimberti; Alberto Luini; Paolo Veronesi; Bernardo Bonanni
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

6.  High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.

Authors:  Martin P Nilsson; Linda Hartman; Ulf Kristoffersson; Oskar T Johannsson; Ake Borg; Karin Henriksson; Elsa Lanke; Håkan Olsson; Niklas Loman
Journal:  Breast Cancer Res Treat       Date:  2014-09-04       Impact factor: 4.872

7.  Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.

Authors:  Jan Drooger; Delal Akdeniz; Jean-Philippe Pignol; Linetta B Koppert; Danielle McCool; Caroline M Seynaeve; Maartje J Hooning; Agnes Jager
Journal:  Breast Cancer Res Treat       Date:  2015-11       Impact factor: 4.872

8.  Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.

Authors:  S R Grobmyer; H J Pederson; S A Valente; Z Al-Hilli; D Radford; R Djohan; R Yetman; C Eng; J P Crowe
Journal:  BJS Open       Date:  2018-11-26

9.  Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.

Authors:  Susan Shanley; Kate McReynolds; Audrey Ardern-Jones; Roger Ahern; Indrajit Fernando; John Yarnold; Gareth Evans; Diana Eccles; Shirley Hodgson; Sue Ashley; Linda Ashcroft; Andrew Tutt; Elizabeth Bancroft; Susan Short; Gerald Gui; Lester Barr; Andrew Baildam; Anthony Howell; Gavin Royle; Lori Pierce; Douglas Easton; Rosalind Eeles
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

10.  Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.

Authors:  Kelly Metcalfe; Shelley Gershman; Parviz Ghadirian; Henry T Lynch; Carrie Snyder; Nadine Tung; Charmaine Kim-Sing; Andrea Eisen; William D Foulkes; Barry Rosen; Ping Sun; Steven A Narod
Journal:  BMJ       Date:  2014-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.